TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31495347

Group type: EXPERIMENTAL
Intervention: 12% RPS
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 24% RPS
Number of subjects: 360

Group type: COMPARATOR
Intervention: 0% RPS (control)
Number of subjects: 360
Study: 27922901

Group type: EXPERIMENTAL
Intervention: TeamSTEPPS training using simulation
Number of subjects: 201
Study: 25009161

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 2.5‐20 mg/d
Number of subjects: 293

Group type: COMPARATOR
Intervention: Conventional antipsychotic (CNV)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 293
Study: 23720078

Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg.kg-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg.kg-1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (physiologic iv)
Number of subjects: 90
Study: 21630032

Group type: EXPERIMENTAL
Intervention: bezafibrate (200 mg twice daily)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids (1 g twice daily)
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 19646281

Group type: EXPERIMENTAL
Intervention: Periodontal treatment (full mouth non-surgical scaling and root planing, systemic antibiotherapy, local antiseptics (chlorhexidine 0.12%), and oral health instructions)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Number of subjects: 150
Study: 17224758

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% without BAC
Number of subjects: 690

Group type: COMPARATOR
Intervention: Travoprost 0.004% with BAC
Number of subjects: 690
Study: 15153205

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg.kg(‐1) before propofol 3 mg.kg(‐1)
Number of subjects: 40
Study: 11599644

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study: 9572229

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg every 4 hours for three doses with or without oxytocin)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion and oxytocin
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 250

Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion
Number of subjects: 250
Study: 7759204

Group type: EXPERIMENTAL
Intervention: Extrusion procedure
Number of subjects: 35

Group type: COMPARATOR
Intervention: Eversion procedures
Number of subjects: 35
Study: 2568016

Group type: EXPERIMENTAL
Intervention: Omeprazole (specific dosage and duration not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery (specific details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy (specific details not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maintenance therapy (specific details not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of drugs (specific details not available)
Number of subjects: 0
Study: 53429

Group type: EXPERIMENTAL
Intervention: Highly buffered acetylsalicylate
Number of subjects: 28
Study: 31453920

Group type: COMPARATOR
Intervention: Traditional King-Devick test (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Randomized King-Devick test
Number of subjects: 96
Study: 31101700

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg three times a day
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaler 20 μg two puffs three times a day
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Honey 30 mg (a spoonful) three times a day
Number of subjects: 668

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 668
Study: 28605109

Group type: EXPERIMENTAL
Intervention: Valnoctamide 1500 mg/d (n=71)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Risperidone 6 mg/d (n=32)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (n=70)
Number of subjects: 173
Study: 25470423

Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (LI-ESWT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Active placebo group (previously placebo)
Number of subjects: 112
Study: 23718084

Group type: EXPERIMENTAL
Intervention: Sinusoidal modulated currents applied to the vegetative nods on the neck
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beginning of the school year clinical conditions
Number of subjects: 0
Study: 21136213

Group type: EXPERIMENTAL
Intervention: Navcap (V 25 mg/m2 on d1 and d8 and C 825 mg/m2 bid D1‐14 q3w) for 4 cycles followed by Navcap (A)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Weekly docetaxel (25 mg/m²/week) for 12 cycles (B)
Number of subjects: 106
Study: 18327566

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency-based chondroplasty (RFC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mechanical shaver debridement (MSD)
Number of subjects: 60
Study: 17519305

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15122531

Group type: EXPERIMENTAL
Intervention: First-void urine specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urethral swabs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semen specimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of all three specimens (first-void urine, urethral swabs, semen)
Number of subjects: 0
Study: 11580908

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9566830

Group type: EXPERIMENTAL
Intervention: Silymarin (450 mg, 150 mg three times per day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 200
Study: 8169656

Group type: EXPERIMENTAL
Intervention: Sustained‐release ferrous sulfate (150 mg) daily for 14 weeks
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo tablets daily for 14 weeks
Number of subjects: 87
Study: 3414573

Group type: EXPERIMENTAL
Intervention: Balloon filled with 400 mL water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Balloon filled with 600 mL water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Balloon filled with 800 mL water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Balloon filled with 0 mL water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Balloon filled with 200 mL water
Number of subjects: 8
Study: 28332246

Group type: EXPERIMENTAL
Intervention: Enhanced stop light diet (eSLD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional diet (CD)
Number of subjects: 150
Study: 27029284

Group type: EXPERIMENTAL
Intervention: One-pill DAPT
Number of subjects: 965

Group type: COMPARATOR
Intervention: Two-pill DAPT
Number of subjects: 965
Study: 24967362

Group type: EXPERIMENTAL
Intervention: MTHFR 677TT genotype
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: ATIC 675T carriers
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Noncurrent smokers
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Patients positive to anti-cyclic citrullinated peptide
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Patients positive to antinuclear antibodies
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Higher health assessment questionnaire score
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug users
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration route
Number of subjects: 233
Study: 22643944

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin at 1.0 g i.v.) only at anesthetic induction
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Antibiotics (cefazolin at 1.0 g i.v. at anesthetic induction and oral amoxicillin at 1 g every 12 hours for 7 days)
Number of subjects: 630

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 630
Study: 21677119

Group type: EXPERIMENTAL
Intervention: Cod liver oil
Number of subjects: 0
Study: 18482233

Group type: EXPERIMENTAL
Intervention: Intravenous propacetamol (40 mg.kg(‐1) via 15 min infusion)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rectal paracetamol (20 mg.kg(‐1) every 6 h)
Number of subjects: 26
Study: 15876311

Group type: EXPERIMENTAL
Intervention: Grass pollen allergoid
Number of subjects: 154
Study: 11996473

Group type: EXPERIMENTAL
Intervention: CMF regimen (cyclophosphamide 100 mg/m2 p.o. on days 1 to 14, methotrexate 40 mg/m2 i.v. on days 1 and 8, 5‐fluorouracil 600 mg/ml i.v. on days 1 and 8; cycles q. 28 days)
Number of subjects: 254
Study: 10076611

Group type: COMPARATOR
Intervention: Carotid endarterectomy with patch closure (CEAP)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Carotid eversion endarterectomy and reimplantation (CEER)
Number of subjects: 310
Study: 7723713

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided liver biopsy using the 0.95 mm cutting biopsy cannula
Number of subjects: 160

Group type: COMPARATOR
Intervention: Percutaneous liver biopsy with the 1.4 mm Menghini needle
Number of subjects: 160
Study: 1669520

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 6986897

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 30269149

Group type: EXPERIMENTAL
Intervention: Intravesical interleukin‐2 (IL‐2) instillations with a marker lesion
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravesical interleukin‐2 (IL‐2) instillations without a marker lesion
Number of subjects: 28
Study: 28686775

Group type: EXPERIMENTAL
Intervention: A/BPO gel 0.3%/2.5%
Number of subjects: 217

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 217
Study: 26000685

Group type: EXPERIMENTAL
Intervention: Subfascial ultrasound-guided stellate ganglion block with 4 mL of 0.375% levobupivacaine (group S)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (group C) without SGB
Number of subjects: 46
Study: 23597267

Group type: EXPERIMENTAL
Intervention: Freeze-dried strawberry powder
Number of subjects: 20

Group type: COMPARATOR
Intervention: Strawberry-flavoured placebo preparations
Number of subjects: 20
Study: 21266447

Group type: EXPERIMENTAL
Intervention: Dietary plant-derived polysaccharide supplement (AC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 19189909

Group type: EXPERIMENTAL
Intervention: Whole-body examination by primary care clinician
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-examination for skin cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Screening for skin cancer
Number of subjects: 0
Study: 17174508

Group type: EXPERIMENTAL
Intervention: Clarithromycin tablet formulation 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin tablet formulation 2
Number of subjects: 0
Study: 15098801

Group type: COMPARATOR
Intervention: Ondansetron solution (4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extemporaneous ondansetron capsule formulation (4 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 16
Study: 11774070

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (1 l/h of a 6% carbohydrate beverage)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Runners reporting URTI
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: All subjects combined
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 98
Study: 9704868

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (m-CPP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8556752

Group type: EXPERIMENTAL
Intervention: Sucrose-containing chewing gum
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no gum)
Number of subjects: 13
Study: 2493523

Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin ointment (NTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 631110

Group type: EXPERIMENTAL
Intervention: High intensity arm cranking exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: High intensity bench stepping with arms at sides
Number of subjects: 17
Study: 31166415

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CHC)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Portland cement with added zirconium oxide (PCZ)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 28455182

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (2 doses of 20 mg/kg)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Topical TXA (3.0 g)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Oral TXA (2 doses of 20 mg/kg)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 560
Study: 27208386

Group type: EXPERIMENTAL
Intervention: DIMS0150 (30 mg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 24184120

Group type: EXPERIMENTAL
Intervention: Foot examinations by primary health care nurses
Number of subjects: 265

Group type: COMPARATOR
Intervention: Age group 51-65 years
Number of subjects: 265

Group type: COMPARATOR
Intervention: Age group >66 years
Number of subjects: 265

Group type: COMPARATOR
Intervention: Consultations by district nurses
Number of subjects: 265

Group type: COMPARATOR
Intervention: Special programme consultations
Number of subjects: 265

Group type: COMPARATOR
Intervention: Consultation length 15-30 min
Number of subjects: 265

Group type: COMPARATOR
Intervention: Consultation length >30 min
Number of subjects: 265

Group type: COMPARATOR
Intervention: Wound care consultations
Number of subjects: 265
Study: 22585649

Group type: EXPERIMENTAL
Intervention: Lichtenstein plus Plug (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lichtenstein Mesh (group A)
Number of subjects: 50
Study: 19766942

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 46

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 46
Study: 17532963

Group type: EXPERIMENTAL
Intervention: MC-1 250 mg
Number of subjects: 901
Study: 15478487

Group type: EXPERIMENTAL
Intervention: Self-etching agents (Prompt‐L Pop, Adper Prompt, Clearfil SE, Prime& Bond NT with NRC, Xeno111, One‐Up Bond, AdheSe)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total etch technique (36% H2PO4)
Number of subjects: 120
Study: 11480451

Group type: EXPERIMENTAL
Intervention: General practitioner letter
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Flag in women's notes prompting discussion by health professionals
Number of subjects: 1158

Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 1158

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1158
Study: 9627258

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (4 mg/kg of 2% lidocaine applied to subglottic, glottic, and supraglottic areas before intubation)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1 mg/kg of 2% lidocaine before extubation)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Normal saline solution (used topically in the first control group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: 0.9% NaCl (given to the second control group)
Number of subjects: 134
Study: 8149770

Group type: EXPERIMENTAL
Intervention: Three levels of protein and phosphorus intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two levels of blood pressure management
Number of subjects: 0
Study: 3276150

Group type: EXPERIMENTAL
Intervention: Oral miconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 12
Study: 29733445

Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 μg/d
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/d
Number of subjects: 81

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 81
Study: 28804199

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin I (hsTnI)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (hsTnT)
Number of subjects: 99
Study: 26304595

Group type: EXPERIMENTAL
Intervention: Angiotensin II type I receptor blocker (ARB) medication
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Increase of eUUN or protein intake during ARB treatment
Number of subjects: 227
Study: 23098134

Group type: COMPARATOR
Intervention: Ingesting all hypertension medications upon awakening
Number of subjects: 2659

Group type: EXPERIMENTAL
Intervention: Ingesting ≥1 hypertension medications at bedtime
Number of subjects: 2659

Group type: EXPERIMENTAL
Intervention: Ingesting all hypertension medications at bedtime
Number of subjects: 2659
Study: 21943044

Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention with high population coverage
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 648
Study: 18315706

Group type: COMPARATOR
Intervention: Bolus intravenous furosemide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Continuous intravenous furosemide infusion
Number of subjects: 42
Study: 16849982

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - smoking cessation intervention
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual Care Group (UC) - control group
Number of subjects: 277
Study: 12690278

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (25 mg/kg every 12 h)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 15887897

Group type: EXPERIMENTAL
Intervention: Cooling application (10 min with a cooling jacket)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Passive recovery (control)
Number of subjects: 14
Study: 10028446

Group type: EXPERIMENTAL
Intervention: Involved ileal mucosa of patients with Crohn's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy and involved ileal mucosa of patients with Crohn's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy mucosa of patients with Crohn's disease
Number of subjects: 0
Study: 7537602

Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily for 24 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2404631

Group type: EXPERIMENTAL
Intervention: Colestipol plus niacin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7000168

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg thrice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 31839533

Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT (PET/CT) scans replacing every other computed tomography (CT) scan
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard follow-up scheme with CT scans (control group)
Number of subjects: 750
Study: 30632692

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 28697785

Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (12 weeks, aerobic and functional exercises in circuit training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 26416265

Group type: EXPERIMENTAL
Intervention: Ipsi‐R (heavy rolling massage on the calf with higher tenderness)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Contra‐R (heavy rolling massage on the contralateral calf)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ipsi‐M (manual massage on the calf with higher tenderness)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham (light stroking of the skin with roller massager on the calf with higher tenderness)
Number of subjects: 150
Study: 24283283

Group type: EXPERIMENTAL
Intervention: 2 minutes brushing
Number of subjects: 0

Group type: COMPARATOR
Intervention: 40 seconds brushing
Number of subjects: 0
Study: 21221621

Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 455
Study: 19647958

Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 17898501

Group type: EXPERIMENTAL
Intervention: ALA-enriched oil (2.6g/14g of ALA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control oil (42g)
Number of subjects: 0
Study: 15483801

Group type: EXPERIMENTAL
Intervention: Lateral joint line injection
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Superomedial injection
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Superolateral injection
Number of subjects: 131
Study: 11679448

Group type: EXPERIMENTAL
Intervention: Energy restriction (WLoss group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Energy restriction plus resistance training (RT + WLoss group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 19
Study: 9044517

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of papaverine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Transdermal nitroglycerin
Number of subjects: 28
Study: 8172713

Group type: EXPERIMENTAL
Intervention: Casodex 50 mg once daily
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Casodex 100 mg/day
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Casodex 150 mg/day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Castration (surgical or medical)
Number of subjects: 304
Study: 30087040

Group type: COMPARATOR
Intervention: CDM Group-I (standard care)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: CDM Group-II (additional interventions including early postpartum follow-up and beta-blocker therapy)
Number of subjects: 269

Group type: COMPARATOR
Intervention: CDM Group-I
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: CDM Group-II
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 269
Study: 27328484

Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 2

Group type: COMPARATOR
Intervention: Modified slow freeze protocol
Number of subjects: 2